Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...
Add Yahoo as a preferred source to see more of our stories on Google. Inside Look is a Star series that takes our readers behind the scenes of some of the most well-known and not-so-well-known places ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results